Pacific Edge Limited
Pacific Edge Limited (PFGTF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
pfgtf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Pacific Edge LimitedYou PFGTF | $188M | N/A | — | — |
 Global Cord Blood Corporation CORBF | $127M | 5.92x | — | $4.12 |
 Lumos Diagnostics Holdings Limited LDXHF | $59M | N/A | — | -$0.01 |
 Orexo AB (publ) ORXOF | $102M | N/A | — | -$3.74 |
 Paradigm Biopharmaceuticals Limited PBIGF | $46M | N/A | — | -$0.06 |
 Shield Therapeutics plc SHIEF | $86M | N/A | — | -$0.02 |
 Senzime AB (publ) SNZZF | $110M | N/A | — | -$0.93 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Pacific Edge Limited (PFGTF) measures how much investors pay for each dollar of the company's trailing earnings. PFGTF's current PE ratio of N/A is calculated by dividing its stock price of $0.16 by its TTM earnings per share of —.
Frequently asked questions
PFGTF pe ratio · 6 questionsPFGTF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.16 and TTM EPS of —. Data sourced from Financial Modeling Prep via PFGTF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Pacific Edge Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09